1. Home
  2. MMS vs PTGX Comparison

MMS vs PTGX Comparison

Compare MMS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMS
  • PTGX
  • Stock Information
  • Founded
  • MMS 1975
  • PTGX 2006
  • Country
  • MMS United States
  • PTGX United States
  • Employees
  • MMS N/A
  • PTGX N/A
  • Industry
  • MMS Business Services
  • PTGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMS Consumer Discretionary
  • PTGX Health Care
  • Exchange
  • MMS Nasdaq
  • PTGX Nasdaq
  • Market Cap
  • MMS 4.8B
  • PTGX 5.0B
  • IPO Year
  • MMS 1997
  • PTGX 2016
  • Fundamental
  • Price
  • MMS $87.05
  • PTGX $86.89
  • Analyst Decision
  • MMS Buy
  • PTGX Strong Buy
  • Analyst Count
  • MMS 1
  • PTGX 9
  • Target Price
  • MMS $90.00
  • PTGX $86.44
  • AVG Volume (30 Days)
  • MMS 604.8K
  • PTGX 929.4K
  • Earning Date
  • MMS 11-20-2025
  • PTGX 11-06-2025
  • Dividend Yield
  • MMS 1.41%
  • PTGX N/A
  • EPS Growth
  • MMS 10.42
  • PTGX N/A
  • EPS
  • MMS 5.51
  • PTGX 0.72
  • Revenue
  • MMS $5,431,276,000.00
  • PTGX $209,217,000.00
  • Revenue This Year
  • MMS $3.64
  • PTGX N/A
  • Revenue Next Year
  • MMS $5.19
  • PTGX $140.23
  • P/E Ratio
  • MMS $15.40
  • PTGX $118.58
  • Revenue Growth
  • MMS 2.36
  • PTGX N/A
  • 52 Week Low
  • MMS $63.77
  • PTGX $33.70
  • 52 Week High
  • MMS $92.50
  • PTGX $93.25
  • Technical
  • Relative Strength Index (RSI)
  • MMS 60.63
  • PTGX 68.57
  • Support Level
  • MMS $77.59
  • PTGX $83.64
  • Resistance Level
  • MMS $84.36
  • PTGX $86.95
  • Average True Range (ATR)
  • MMS 2.27
  • PTGX 2.97
  • MACD
  • MMS 0.59
  • PTGX 0.02
  • Stochastic Oscillator
  • MMS 98.73
  • PTGX 99.62

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: